HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Adib H. Sabbagh Paul Shuttleworth Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabbagh, A. H. Articles by Gabrhel, W. Search for Related Content PubMed PubMed Citation Articles by Sabbagh, A. H. Articles by Gabrhel, W.

Ann Thorac Surg 1984;37:466-468
© 1984 The Society of Thoracic Surgeons

---

Articles

Fresh Frozen Plasma: A Solution to Heparin Resistance during Cardiopulmonary Bypass

From the Associates in Thoracic Surgery, P.C., Tucson, AZ

Accepted for publication December 9, 1983.

^* Address reprint requests to Dr. Sabbagh, 5200 E Grant Rd, Suite 612, Tucson, AZ 85712

The reasons for the highly variable response of patients to heparin remain incompletely understood. Empirical maintenance of the activated clotting time (ACT) at levels of 400 to 480 seconds appears to be safe for cardiopulmonary bypass (CPB). For patients with ACT responses lower than predicted for initial heparin doses, titration with additional heparin has been customary. In 44 patients undergoing cardiopulmonary bypass, 20 patients were identified as having initial ACTs of 300 seconds or less after receiving 300 units per kilogram of heparin. In 11 of them, ACTs were titrated to 400 to 480 seconds with additional heparin. Nine were given 2 units of fresh frozen plasma shortly after institution of CPB. In this group, there was significant augmentation of the ACT immediately after infusion of plasma. No differences in total heparin dosages given during CPB were found between 24 control patients with initially acceptable ACTs and the group receiving fresh frozen plasma. In contrast, more heparin was necessary in the patients with a low ACT titrated with heparin alone. Data also indicated that protamine sulfate requirements were substantially lower after administration of plasma than were those in either the control or the heparin-titrated, low ACT group. Fresh frozen plasma appears to "normalize" the heparin–ACT dose-response curve in heparin-resistant patients and to lessen total heparin requirements during CPB.

This article has been cited by other articles:

				V. A. Ferraris, J. R. Brown, G. J. Despotis, J. W. Hammon, T. B. Reece, S. P. Saha, H. K. Song, E. R. Clough, L. J. Shore-Lesserson, L. T. Goodnough, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines Ann. Thorac. Surg., March 1, 2011; 91(3): 944 - 982. [Abstract] [Full Text] [PDF]

				B. D. Spiess Treating Heparin Resistance With Antithrombin or Fresh Frozen Plasma Ann. Thorac. Surg., June 1, 2008; 85(6): 2153 - 2160. [Abstract] [Full Text] [PDF]

				S. T. Morozowich, B. S. Donahue, and I. J. Welsby Genetics of coagulation: considerations for cardiac surgery. Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 297 - 313. [Abstract] [PDF]

				M.S. Avidan, J.H. Levy, H. van Aken, R.O. Feneck, R.D. Latimer, E. Ott, E. Martin, D.E. Birnbaum, L.J. Bonfiglio, D.K. Kajdasz, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 107 - 113. [Abstract] [Full Text] [PDF]

				J. H. Levy, F. Montes, F. Szlam, and C. D. Hillyer The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy Anesth. Analg., May 1, 2000; 90(5): 1076 - 1079. [Abstract] [Full Text] [PDF]

				M Ranucci, A Cazzaniga, G Isgro, A Ditta, A Boncilli, M Cotza, and S Brozzi Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients Perfusion, September 1, 1999; 14(5): 357 - 362. [Abstract] [PDF]

				A. S. Weisinger and J. H. Levy Current Hematologic Issues in Cardiac Surgery and Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1998; 2(4): 259 - 271. [Abstract] [PDF]

				P. Robbins, M. Forrest, and D. Royston Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 295 - 318. [Abstract] [PDF]

				M. S. Irani Antithrombin Concentrates in Heparin-Resistant Cardiopulmonary Bypass Patients Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 103 - 106. [Abstract] [PDF]

				G. J. Despotis, J. H. Joist, D. Joiner-Maier, A. L. Alsoufiev, A. N. Triantafillou, L. T. Goodnough, S. A. Santoro, and D. G. Lappas Effect of aprotinin on activated clotting time whole blood and plasma heparin measurements Ann. Thorac. Surg., January 1, 1995; 59(1): 106 - 111. [Abstract] [PDF]

				S. Metz and A. S. Keats Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding Ann. Thorac. Surg., March 1, 1990; 49(3): 440 - 444. [Abstract] [PDF]

				C. Aren Review article : Heparin and protamine during cardiac surgery Perfusion, July 1, 1989; 4(3): 171 - 181. [PDF]